Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Steve Kulp | M | - |
Peptilogics, Inc.
Peptilogics, Inc. Miscellaneous Commercial ServicesCommercial Services Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA. | 3 years |
Stefan Röever | M | - |
Peptilogics, Inc.
Peptilogics, Inc. Miscellaneous Commercial ServicesCommercial Services Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA. | - |
Dietrich Stephan | M | 54 |
Peptilogics, Inc.
Peptilogics, Inc. Miscellaneous Commercial ServicesCommercial Services Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA. | 8 years |
Catherine Mott | F | - |
Peptilogics, Inc.
Peptilogics, Inc. Miscellaneous Commercial ServicesCommercial Services Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA. | - |
Jason Camm | M | - |
Peptilogics, Inc.
Peptilogics, Inc. Miscellaneous Commercial ServicesCommercial Services Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA. | - |
Nicholas Pachuda | M | - |
Peptilogics, Inc.
Peptilogics, Inc. Miscellaneous Commercial ServicesCommercial Services Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA. | - |
Hannes H. | M | - |
Peptilogics, Inc.
Peptilogics, Inc. Miscellaneous Commercial ServicesCommercial Services Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA. | 6 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 7 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jonathan Steckbeck
- Personal Network